The Significance of Gamma-Glutamyl Transpeptidase to Lymphocyte Count Ratio in the Early Postoperative Recurrence Monitoring and Prognosis Prediction of AFP-Negative Hepatocellular Carcinoma
Overview
Authors
Affiliations
Background: Currently, there is still a lack of effective biomarkers for the recurrence monitoring and survival prognosis assessment of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP)-negative (≤20 ng/mL) after radical resection.
Methods: The clinicopathological data of 606 patients (303 in the AFP-negative group and 303 in the AFP-positive group) who underwent radical resection of HCC were analyzed retrospectively.
Results: The gamma-glutamyl transpeptidase to lymphocyte count ratio (GLR) of patients in the AFP-negative group was lower than that in the AFP-positive group ( <0.001). The GLR level of the early-recurrence group was higher than that of the non-early-recurrence group ( =0.003). GLR had fair accuracy in predicting the early-recurrence of HCC patients [c-index=0.654 (95% CI=0.606-0.702); AUC=0.681 (95% CI=0.625-0.733)]. Univariate analysis showed that patients with tumor size <5 cm, no microvascular invasion, single tumor, no metastasis, BCLC stage 0-A, no recurrence, and GLR ≤45.0 had longer disease-free survival (DFS) and overall survival (OS) among AFP-negative HCC patients. In addition, multivariate Cox proportional hazards regression analysis showed that tumor size <5 cm ( =0.003), no recurrence ( <0.001), and GLR <45.0 ( <0.001) were independent predictors of longer OS.
Conclusion: GLR may be a potential indicator for early recurrence monitoring and prognosis evaluation in HCC patients with AFP-negative after radical resection.
Cao S, Zhou Z, Chen C, Li W, Liu J, Xu J World J Surg Oncol. 2024; 22(1):240.
PMID: 39244533 PMC: 11380786. DOI: 10.1186/s12957-024-03523-1.
Xiong Y, Qiao W, Mei T, Li K, Jin R, Zhang Y J Hepatocell Carcinoma. 2024; 11:1375-1388.
PMID: 39005969 PMC: 11245575. DOI: 10.2147/JHC.S465962.
Qiao W, Xiong Y, Li K, Jin R, Zhang Y J Hepatocell Carcinoma. 2024; 11:1113-1125.
PMID: 38887683 PMC: 11182039. DOI: 10.2147/JHC.S465069.
Yan X, Li Y, Qin W, Liao J, Fan J, Xie Y BMC Cancer. 2024; 24(1):700.
PMID: 38849749 PMC: 11157869. DOI: 10.1186/s12885-024-12436-x.
Zhang B, Xue J, Xu B, Chang J, Li X, Huang Z Sci Rep. 2024; 14(1):10726.
PMID: 38730095 PMC: 11087499. DOI: 10.1038/s41598-024-61615-0.